Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Chippenham, UK – 21 May 2013: Vectura Group plc (“Vectura”; LSE: VEC), announces that, after 11 years
as Chief Financial Officer (CFO), helping to list Vectura on the London Stock Exchange and contributing to
the growth of the Company, Anne Hyland is stepping down from her Board position and as CFO and
Company Secretary at the end of June. Paul Oliver, currently Financial Controller, will be appointed to the
Board as CFO and Company Secretary from July 1, 2013.
Anne has played a central role in the formation of Vectura's new venture in China, Tianjin Kinnovata
Pharmaceutical Company Limited (“Kinnovata”), which was announced on May 13, 2013. Anne will continue
to have an involvement with Kinnovata.
Paul joined Vectura in 2006 and has managed Vectura’s finances for the last seven years. In his role as
Group Financial Controller, Paul has worked closely with Anne, Vectura’s Leadership Team and the Board
on all aspects of Vectura’s operations and strategy development. Prior to joining Vectura, Paul worked in
professional practice and is a Fellow of the Association of Chartered Certified Accountants.
There is no further information required to be disclosed pursuant to LR 9.6.13.
Jack Cashman, Chairman of Vectura, commented:
“On behalf of the Board, I thank Anne for her considerable contribution to the transformation of Vectura over
the last eleven years, most recently her central role in the establishment of Kinnovata. Since 2002, Vectura
has grown from a small business with a limited pipeline into a leading developer of inhaled therapies,
substantial revenues and strong cash resources. We are fortunate and pleased to be able to appoint Paul
Oliver, a well-qualified internal successor to Anne, and look forward to working with Paul on Vectura’s
Vectura Group plc +44 (0)1249 667700
Chris Blackwell, Chief Executive
Karl Keegan, Corporate Development Director
FTI Consulting +44 (0)20 7831 3113
John Dineen / Ben Atwell / Simon Conway
Vectura Group plc and its subsidiaries (“Vectura” or the “Group”) is a product development company that
focuses on the development of pharmaceutical therapies for the treatment of airway diseases. This growing
market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in
excess of $30 billion worldwide.
Vectura has seven products marketed by its partners and a portfolio of drugs in clinical development, a
number of which have been licensed to major pharmaceutical companies. Vectura has development
collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz
(the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK) and Tianjin King York Group Company
Vectura seeks to develop certain programmes itself where this will optimise value. Vectura’s formulation and
inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this
complements Vectura’s business strategy. For further information, please visit Vectura’s website at
This press release contains forward-looking statements, including statements about the discovery,
development and commercialisation of products. Various risks may cause Vectura's actual results to differ
materially from those expressed or implied by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent protection for inventions; commercial limitations
imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to
develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to
market products and services resulting from development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialisation activities; and product initiatives by
competitors. As a result of these factors, prospective investors are cautioned not to rely on any forwardlooking
statements. We disclaim any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is provided by RNS
The company news service from the London Stock Exchange
Help employers find you! Check out all the jobs and post your resume.